SILVER LACTATE MONOHYDRATE

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H5O3.Ag.H2O
Molecular Weight	214.9535
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Ag+].CC(O)C([O-])=O

InChI

InChIKey=RKVLDPOOWODDMR-UHFFFAOYSA-M

InChI=1S/C3H6O3.Ag.H2O/c1-2(4)3(5)6;;/h2,4H,1H3,(H,5,6);;1H2/q;+1;/p-1

HIDE SMILES / InChI

Molecular Formula	Ag
Molecular Weight	107.8682
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.purebio.com/assets/001/5202.pdfhttp://google.com/patents/CN102923966Bhttps://www.ncbi.nlm.nih.gov/pubmed/19278981https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988The legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738
Curator's Comment: description was created based on several sources, including https://www.drugs.com/monograph/silver-nitrate.html | https://www.ncbi.nlm.nih.gov/pubmed/18245232

Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cellular response to silver ion 16 Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232	Substrate 661
tooth mineralization 16 Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26897901	Substrate 661
cellular response to silver ion 16 Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232	Substrate 661
tooth mineralization 16 Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24373700	Substrate 661
cellular response to silver ion 16 Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232	Substrate 661
cellular response to silver ion 16 Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232	Substrate 661

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Dental caries 44 Sources: https://clinicaltrials.gov/ct2/show/NCT01446107	Primary	Approved 8429	Advantage Arrest Silver Diamine Fluoride Approved Use Unknown
Dentinal hypersensitivity 16 Sources: http://health.mo.gov/living/families/oralhealth/pdf/silver-diamine-fluoride.pdf	Primary	Approved 8429	Advantage Arrest Silver Diamine Fluoride Approved Use Unknown
Dental caries 44 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26687774	Primary	Phase I 428	Unknown Approved Use Unknown
Bacterial Infections 63 Sources: https://www.purebio.com/assets/001/5202.pdf	Curative	Not Provided 504	Unknown Approved Use Unknown
Dermatophyte infection 18 Sources: http://www.prnewswire.com/news-releases/pure-bioscience-and-therapeutics-inc-expand-silver-dihydrogen-citrate-pharmaceutical-product-development-initiative-to-include-athletes-foot-nail-fungus-and-antimicrobial-skin-wash-products-55885657.html	Curative	Not Provided 504	Unknown Approved Use Unknown
Unknown 2578
Infections of the mucous membranes 16 Sources: https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~Hcwr0m:1:ther	Primary	Not Provided 504	Colloidal silver iodide Approved Use Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Inflammatory conditions of the eye, ear, and nose 16 Sources: https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~Hcwr0m:1:ther	Primary	Not Provided 504	Colloidal silver iodide Approved Use Solution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose.
Burn 40 Sources: http://reference.medscape.com/drug/silver-nitrate-343589	Palliative	Approved 8429	Unknown Approved Use Antiseptic Wound Cauterization
Ophthalmia neonatorum 16 Sources: https://www.drugs.com/monograph/silver-nitrate.html	Primary	Approved 8429	Unknown Approved Use Prophylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth.

PubMed

Title	Date	PubMed
Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli.	2008 Apr	18245232
Development of silica-coated silver iodide nanoparticles and their biodistribution.	2012 Dec	23132228
UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent.	2016 Jan	26897901

Patents

Sample Use Guides

In Vivo Use Guide

Topical as a 1:80 dilution (30 ppm ionic silver).

Route of Administration: Topical

In Vitro Use Guide

10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:08:38 GMT 2023` Edited by `admin` on `Sat Dec 16 10:08:38 GMT 2023`
Record UNII	67E6H10EYR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SILVER LACTATE MONOHYDRATE

Systematic Name

English

SILVER, (2-(HYDROXY-.KAPPA.O)PROPANOATO-.KAPPA.O)-, HYDRATE (1:1)

Common Name

English

SILVER LACTATE MONOHYDRATE [MI]

Common Name

English

Code System Code Type Description

CAS

19025-99-1

Created by admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023

PRIMARY

PUBCHEM

22600159

Created by admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023

PRIMARY

FDA UNII

67E6H10EYR

Created by admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023

PRIMARY

MERCK INDEX

m9926

Created by admin on Sat Dec 16 10:08:38 GMT 2023 , Edited by admin on Sat Dec 16 10:08:38 GMT 2023

PRIMARY

Merck Index

Related Record Type Details


					1O6T8HG11V

SILVER LACTATE

ANHYDROUS->SOLVATE

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides